文献速递前列腺增生与排尿功能障碍

米拉贝隆与抗毒蕈碱药物在膀胱过度活动症患者中的持续性与依从性比较:英国临床实践中的回顾性观察研究

Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
PubMed 文献 · Eur Urol · 2017-02-11

基于英国临床实践研究数据链GOLD数据库的回顾性纵向观察研究,纳入21996例膀胱过度活动症患者,比较米拉贝隆与托特罗定缓释片及其他抗毒蕈碱药物的持续性与依从性。结果显示米拉贝隆的中位停药时间显著长于托特罗定缓释片及其他抗毒蕈碱药物,12个月持续率和药物持有率也显著更高。

要点

  • 米拉贝隆中位停药时间169天,显著长于托特罗定缓释片56天(调整HR 1.55)。
  • 米拉贝隆12个月持续率和药物持有率均显著高于所有抗毒蕈碱药物。
  • 局限性包括回顾性设计、使用处方记录估计结局、无法获取停药原因。

核心结论

  • 在英国膀胱过度活动症患者中,米拉贝隆的持续性和依从性在统计学上显著高于托特罗定缓释片和其他抗毒蕈碱药物。

研究设计与样本

  • 回顾性、纵向、观察性研究,使用英国临床实践研究数据链GOLD数据库的匿名数据。
  • 纳入标准:年龄≥18岁,2013年5月1日至2014年6月29日期间至少开具1次目标膀胱过度活动症药物处方,且索引处方日期前后12个月连续入组。
  • 研究人群包括21996例符合条件的患者。
  • 干预药物包括米拉贝隆、达非那新、非索罗定、黄酮哌酯、奥昔布宁缓释或速释、丙哌维林、索利那新、托特罗定缓释或速释、曲司氯铵。
  • 主要终点为持续性(至停药时间);次要终点包括12个月持续率和依从性(用药持有率MPR评估)。

主要发现

  • 非匹配分析中,米拉贝隆的中位停药时间显著长于托特罗定缓释片:米拉贝隆169天(四分位距41-未达到)vs 托特罗定缓释片56天(四分位距28-254),调整HR 1.55,95%CI 1.41-1.71,p<0.0001。
  • 非匹配分析中,米拉贝隆的中位停药时间显著长于其他抗毒蕈碱药物(范围30-78天;调整HR范围1.24-2.26,所有比较p<0.0001)。
  • 米拉贝隆的12个月持续率和MPR均显著高于所有抗毒蕈碱药物。

局限性

  • 回顾性设计。
  • 使用处方记录估计结局。
  • 无法获取停药原因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Persistence with antimuscarinic therapy in overactive bladder (OAB) is poor, but may be different for mirabegron, a β3-adrenoceptor agonist with a different adverse event profile. OBJECTIVE: To compare persistence and adherence with mirabegron versus tolterodine extended release (ER) and other antimuscarinics in routine clinical practice over a 12-mo period. DESIGN, SETTING, AND PARTICIPANTS: Retrospective, longitudinal, observational study of anonymised data from the UK Clinical Practice Research Datalink GOLD database. Eligibility: age ≥18 yr, ≥1 prescription for target OAB drug (between May 1, 2013 and June 29, 2014), and 12-mo continuous enrolment before and after the index prescription date. INTERVENTIONS: Mirabegron, darifenacin, fesoterodine, flavoxate, oxybutynin ER or immediate-release (IR), propiverine, solifenacin, tolterodine ER or IR, and trospium chloride. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was persistence (time to discontinuation). Secondary endpoints included 12-mo persistence rates and adherence (assessed using medication possession ratio, MPR). Cox proportional-hazards regression models and logistic regression models adjusted for potential confounding factors were used to compare cohorts. Analyses were repeated after 1:1 matching. RESULTS AND LIMITATIONS: The study population included 21996 eligible patients. In the unmatched analysis, the median time-to-discontinuation was significantly longer for mirabegron (169 d, interquartile range [IQR] 41-not reached) compared to tolterodine ER (56 d, IQR 28-254; adjusted hazard ratio [HR] 1.55, 95% confidence interval 1.41-1.71; p<0.0001) and other antimuscarinics (range 30-78 d; adjusted HR range 1.24-2.26, p<0.0001 for all comparisons). The 12-mo persistence rates and MPR were also significantly greater with mirabegron than with all the antimuscarinics. Limitations include the retrospective design, use of prescription records to estimate outcomes, and inability to capture reasons for discontinuation. CONCLUSIONS: Persistence and adherence were statistically significantly greater with mirabegron than with tolterodine ER and other antimuscarinics prescribed for OAB in the UK. PATIENT SUMMARY: This study assessed persistence and adherence (or compliance) with medications prescribed for OAB in a large UK population. We found that patients prescribed mirabegron remained on treatment for longer and showed greater adherence than those prescribed traditional antimuscarinics.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Chapple CR, Nazir J, Hakimi Z, et al. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice. Eur Urol. 2017. PMID: 28196724. doi:10.1016/j.eururo.2017.01.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。